{"protocolSection":{"identificationModule":{"nctId":"NCT05719883","orgStudyIdInfo":{"id":"QX2022-021-02"},"organization":{"fullName":"Beijing Tiantan Hospital","class":"OTHER"},"briefTitle":"Evaluating the Safety and Efficacy of the Maurora® DES in ICAS","officialTitle":"A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)","acronym":"Maurora ICAS"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-02-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-01-31","studyFirstSubmitQcDate":"2023-01-31","studyFirstPostDateStruct":{"date":"2023-02-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-19","lastUpdatePostDateStruct":{"date":"2023-09-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Beijing Tiantan Hospital","class":"OTHER"},"collaborators":[{"name":"Alain Medical (Beijing) Co., Ltd.","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the RCT trial is to evaluate whether implantation of drug-eluting stent (DES) is more efficacious than bare metal stent (BMS) in prevention of in-stent restenosis (ISR) and improvement of outcomes for symptomatic intracranial atherosclerotic stenosis. This trial is prospective, multi-center, randomized 1:1 single blind trial using Maurora sirolimus eluting stent versus Apollo bare metal stent conducted in approximately 10 interventional neurology centers in China. The study is sponsored by Alain Medical (Beijing) Co., Ltd.","detailedDescription":"This trial is a prospective, multi-center, 1:1 randomized using drug-eluting (Sirolimus) stent versus bare metal stent (BMS) to treat intracranial stenosis of 70-99% degree. The primary endpoint is in-stent restenosis rate(ISR) within 12 months after revascularization procedure of the qualifying lesion during follow-up."},"conditionsModule":{"conditions":["Intracranial Arteriosclerosis","Stroke (CVA) or TIA"],"keywords":["Intracranial Atherosclerotic stenosis","Drug-eluting stent","Ischemia stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":156,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Maurora® Sirolimus Eluting Stent System","type":"EXPERIMENTAL","description":"Device: Maurora® Sirolimus Eluting Stent System A sirolimus eluting intracranial stent system with platform is made of L605 CoCr alloys.","interventionNames":["Device: Maurora® Sirolimus Eluting Stent System"]},{"label":"APOLLO™ Intracranial Stent System","type":"ACTIVE_COMPARATOR","description":"Device: Apollo Intracranial Stent System A 316L stainless steel balloon-expandable intracranial stent system.","interventionNames":["Device: APOLLO™ Intracranial Stent System"]}],"interventions":[{"type":"DEVICE","name":"Maurora® Sirolimus Eluting Stent System","description":"The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.","armGroupLabels":["Maurora® Sirolimus Eluting Stent System"],"otherNames":["Maurora"]},{"type":"DEVICE","name":"APOLLO™ Intracranial Stent System","description":"The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.","armGroupLabels":["APOLLO™ Intracranial Stent System"],"otherNames":["APOLLO"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"In-stent restenosis rate(ISR) within 12 months after procedure","description":"Angiographic evidence of in-stent stenosis ≥50% at 12 months after procedure","timeFrame":"12 months after procedure"}],"secondaryOutcomes":[{"measure":"Implantation success rate","description":"Implantation success was defined as successful arrival of stent to the lesion and subsequent release of the stent delivery system.","timeFrame":"During the procedure"},{"measure":"Technical success rate","description":"Technical success was defined as successful arrival of stent to the lesion and subsequent release of the stent delivery system with a residual stenosis of \\<30%.","timeFrame":"During the procedure"},{"measure":"Clinical success rate","description":"Clinical success was defined as successful arrival of stent to the lesion and subsequent release of the stent delivery system with a residual stenosis of \\<30%, and free from major adverse event within 12 months after procedure.\n\nsystem with a residual stenosis of \\<30%","timeFrame":"12 months after procedure"},{"measure":"Stroke or death within 30 days after procedure","description":"Any stroke included ischemic stroke or/and symptomatic brain hemorrhage and all-cause death.","timeFrame":"within 30 days after procedure"},{"measure":"Stroke in the target vessel territory or death within 30 days after procedure","description":"Death or any stroke events related to target vessel after revascularization.","timeFrame":"within 30 days after procedure"},{"measure":"Ischemic stroke in the target vessel territory between 31 day to 1 year after procedure","description":"Any ischemic stroke events related to target vessel after revascularization.","timeFrame":"between 31 day to 1 year after procedure"},{"measure":"Ischemic stroke in other vessel territory between 31 day to 1 year after procedure","description":"Any ischemic stroke events unrelated to target vessel after revascularization.Ischemic stroke is defined as a new focal neurological deficit of sudden onset, that is associated with infarction lesion on CT or MRI. Ischemic strokes are classified as in or out of the territory of the symptomatic intracranial artery.","timeFrame":"between 31 day to 1 year after procedure"},{"measure":"Any ischemic stroke between 31 day to 1 year after procedure","description":"Ischemic stroke is defined as a new focal neurological deficit of sudden onset, that is associated with infarction lesion on CT or MRI. Ischemic strokes are classified as in or out of the territory of the symptomatic intracranial artery.","timeFrame":"between 31 day to 1 year after procedure"},{"measure":"Any subdural, epidural hemorrhage or a systemic hemorrhage between 31 day to 1 year after procedure","description":"Any subdural or epidural hemorrhage or a systemic hemorrhage is required hospitalization, blood transfusion, or surgery.","timeFrame":"between 31 day to 1 year after procedure"},{"measure":"Death between 31 day to 1 year after procedure","description":"All-cause death.","timeFrame":"between 31 day to 1 year after procedure"},{"measure":"Transient Ischemic Attack within 1 year after the procedure","description":"A transient ischemic attack (TIA) is a temporary period of symptoms similar to those of a stroke. A TIA usually lasts only a few minutes up to 24 hours and doesn't cause permanent damage.","timeFrame":"1 year after the procedure"},{"measure":"Functional outcome measured by the modified Rankin Scale","description":"Focus on difference between 1 month and 12 months after procedure. The range of modified Rankin Scale was from 0 to 6. 0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6 -Dead. A higher score indicates worse a outcome.","timeFrame":"1 and 12 months after procedure"}],"otherOutcomes":[{"measure":"Complications of stent implantation procedure","description":"Any complications including vascular complications of assess the intracranial arteries, Allergic reactions or hypersensitivity to agents or device in procedure, complications of intracranial arteries, infection, fever, bleeding and other events.","timeFrame":"12 months after procedure"},{"measure":"Stroke","timeFrame":"12 months after procedure"},{"measure":"adverse events (AE) and serious adverse events (SAE)","timeFrame":"12 months after procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age from 18 to 85 years;\n2. Symptomatic intracranial atherosclerosis (Definition: Stroke or transient ischemic attack \\[TIA\\] associated with intracranial atherosclerosis within 90 days of enrollment);\n3. A major intracranial artery (carotid artery, MCA stem \\[M1\\], vertebral artery, or basilar artery) with 70% to 99% stenosis on the angiography (According to WASID method);\n4. The target lesion length ≤15 mm and the vessel diameter between 2.5mm and 5.0mm, distal vessel diameter \\>1.5mm;\n5. Only one stent planned for the target lesion;\n6. A Modified Rankin Score of ≤ 3;\n7. Patients understand the purpose and requirements of the study, and can make him/herself understood, and has provided informed consent.\n\nExclusion Criteria:\n\n1. Ischemic stroke within 2 weeks before the procedure;\n2. Tandem extracranial or intracranial stenosis (70%-99%) of the target lesion;\n3. Patients with stroke caused by perforating artery occlusion;\n4. Severe calcification at target lesion;\n5. Any history of brain parenchymal or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 6 weeks;\n6. History of stenting or angioplasty of an intracranial artery;\n7. Intracranial tumor, aneurysm or intracranial arteriovenous malformation;\n8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: moya-moya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, post-partum vascular disease, suspected vasospasm, suspicious embolism recanalization;\n9. Presence of any unequivocal cardiac source of embolism (e.g. atrial fibrillation);\n10. Those who cannot tolerate general anesthesia due to insufficiency of cardiac or pulmonary function, not suitable for procedure;\n11. Known allergy or contraindication to heparin, aspirin, ticlopidine, ticagrelor, sirolimus, anaesthetics and contrast agents;\n12. Severe renal and hepatic insufficiency (ALTor AST \\> 3x upper limit, creatinine \\> 1.5x upper limit);\n13. Major surgery within the past 30 days or planned within 90 days, or requiring simultaneous intervention to renal artery, iliac artery, and coronary artery;\n14. Life expectancy \\<12 months;\n15. Pregnant or lactating women, or planning for pregnancy;\n16. Participated in another investigational device or drug study within 30 days;\n17. According to the judgement of the investigator, other situations that are not suitable for enrollment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Baixue Jia, MD","role":"CONTACT","phone":"15010125093","email":"beckyberry@163.com"}],"overallOfficials":[{"name":"Ning Ma, MD","affiliation":"Beijing Tiantan Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beijing Tiantan Hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100070","country":"China","contacts":[{"name":"Baixue Jia, MD","role":"CONTACT","phone":"15010125093","email":"beckyberry@163.com"},{"name":"Ning Ma","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Baixue Jia","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"references":[{"pmid":"31248666","type":"BACKGROUND","citation":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Erratum In: Lancet. 2020 Jul 4;396(10243):26."},{"pmid":"30871944","type":"BACKGROUND","citation":"GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11."},{"pmid":"15800226","type":"BACKGROUND","citation":"Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi: 10.1056/NEJMoa043033."},{"pmid":"21899409","type":"BACKGROUND","citation":"Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7. Erratum In: N Engl J Med. 2012 Jul 5;367(1):93."},{"pmid":"23277374","type":"BACKGROUND","citation":"Shin YS, Kim BM, Suh SH, Jeon P, Kim DJ, Kim DI, Kim BS, Kim KH, Heo JH, Nam HS, Kim YD. Wingspan stenting for intracranial atherosclerotic stenosis: clinical outcomes and risk factors for in-stent restenosis. Neurosurgery. 2013 Apr;72(4):596-604; discussion 604. doi: 10.1227/NEU.0b013e3182846e09."},{"pmid":"23963335","type":"BACKGROUND","citation":"Jin M, Fu X, Wei Y, Du B, Xu XT, Jiang WJ. Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis. Stroke. 2013 Nov;44(11):2990-4. doi: 10.1161/STROKEAHA.113.001824. Epub 2013 Aug 20."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002537","term":"Intracranial Arteriosclerosis"},{"id":"D000001161","term":"Arteriosclerosis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000020765","term":"Intracranial Arterial Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5476","name":"Intracranial Arteriosclerosis","asFound":"Intracranial Arteriosclerosis","relevance":"HIGH"},{"id":"M4159","name":"Arteriosclerosis","asFound":"Arteriosclerosis","relevance":"HIGH"},{"id":"M6165","name":"Constriction, Pathologic","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M22211","name":"Intracranial Arterial Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000020123","term":"Sirolimus"}],"ancestors":[{"id":"D000000900","term":"Anti-Bacterial Agents"},{"id":"D000000890","term":"Anti-Infective Agents"},{"id":"D000000903","term":"Antibiotics, Antineoplastic"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000000935","term":"Antifungal Agents"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M21650","name":"Sirolimus","asFound":"While","relevance":"HIGH"},{"id":"M3912","name":"Anti-Bacterial Agents","relevance":"LOW"},{"id":"M3904","name":"Anti-Infective Agents","relevance":"LOW"},{"id":"M3914","name":"Antibiotics, Antitubercular","relevance":"LOW"},{"id":"M5942","name":"Clotrimazole","relevance":"LOW"},{"id":"M11486","name":"Miconazole","relevance":"LOW"},{"id":"M3944","name":"Antifungal Agents","relevance":"LOW"},{"id":"M9902","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}